Results 31 to 40 of about 7,946 (150)

Cost-effectiveness of retreatment with varenicline after failure with or relapse after initial treatment for smoking cessation

Preventive Medicine Reports, 2015
Objectives: A recent trial showed the clinical benefit of retreatment with varenicline in subjects failing on the initial treatment, or relapsing after initial success.
Lieven Annemans, Sophie Marbaix, Kristiaan Nackaerts, Pierre Bartsch   +3 more
doaj   +1 more source

Comparative effectiveness, safety and acceptability of pharmacological and psychosocial interventions for the treatment of cannabis use disorder: A network meta‐analysis

Addiction, EarlyView.
Abstract Aim Our primary aim was to conduct a network meta‐analysis (NMA) for the effectiveness, safety and acceptability of all psychosocial interventions and all pharmacotherapies for cannabis use disorder (CUD). Methods We conducted a NMA of studies identified from two completed systematic reviews examining the effectiveness, safety and ...
Monika Halicka, Francesca Spiga, Tom P. Freeman, Suzanne Nielsen, Jelena Savović, Julian P. T. Higgins, Deborah M. Caldwell   +6 more
wiley   +1 more source

Beyond abstinence: Redefining success in cannabis use disorder treatment

Addiction, EarlyView.
Abstract Background Over two decades of pharmacotherapy research has yet to yield a consistently effective medication for cannabis use disorder (CUD), in part because clinical trials have frequently prioritized abstinence as a primary or key endpoint.
Tobias B. Atkin, Frances R. Levin, John Mariani, Christina A. Brezing   +3 more
wiley   +1 more source

Systemic medications associate with surgically treated cataract among adults over 50 years in Finland

Acta Ophthalmologica, EarlyView.
Abstract Purpose To identify associations between systemic drugs and cataract surgery in Finland. Methods A historic cohort study based on administrative data. Endpoint event was cataract surgery. Use of drugs in question was based on redeemed prescriptions and consisted of 156 drugs.
Antti Riikonen, Jari Haukka, Tuomas Lilius, Sirpa Loukovaara   +3 more
wiley   +1 more source

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source

Novel Histopathologic Features of Diffuse Blue‐Gray Hyperpigmentation Associated With Kratom Use: A Case Report and Literature Review

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Background Drug‐induced hyperpigmentation accounts for 10%–20% of acquired pigmentary disorders and can be misdiagnosed for other causes such as melasma, post inflammatory changes, or heavy metal deposition. Kratom (Mitragyna speciosa), a Southeast Asian plant with an opioid‐like profile, has been increasingly used in the United States for ...
Rita Kamoua, Kristen Paradine, Craig A. Rohan, Mary McDaniel, Diane Perkins   +4 more
wiley   +1 more source

Nicotine receptor partial agonists for smoking cessation

São Paulo Medical Journal
BACKGROUND: Nicotine receptor partial agonists may help people to stop smoking by a combination of maintaining moderate levels of dopamine to counteract withdrawal symptoms (acting as an agonist) and reducing smoking satisfaction (acting as an antagonist)
Kate Cahill, Lindsay F. Stead, Tim Lancaster, Igor Bastos Polonio   +3 more
doaj   +1 more source

Varenicline versus nicotine replacement therapy for long-term smoking cessation: an observational study using the Clinical Practice Research Datalink

Health Technology Assessment, 2020
Background: Smoking is the leading avoidable cause of illness and premature mortality. The first-line treatments for smoking cessation are nicotine replacement therapy and varenicline.
Neil M Davies, Amy E Taylor, Gemma MJ Taylor, Taha Itani, Tim Jones, Richard M Martin, Marcus R Munafò, Frank Windmeijer, Kyla H Thomas   +8 more
doaj   +1 more source

Awareness and early implementation of the European AIDS Clinical Society Guidance on statin use in HIV for the primary prevention of cardiovascular disease: A cross‐sectional survey of HIV clinicians in Europe

HIV Medicine, EarlyView.
Abstract Objectives Cardiovascular disease (CVD) is a major comorbidity and leading cause of morbidity and mortality in people with HIV (PWH). The REPRIEVE trial demonstrated that statin therapy significantly reduces cardiovascular events in PWH, prompting updated recommendations from major international societies.
Jasmini Alagaratnam, Abiu Sempere, Susanne Dam Nielsen, Esteban Martinez   +3 more
wiley   +1 more source

Visual hallucinations associated with varenicline: a case report

Journal of Medical Case Reports, 2009
Introduction Varenicline is widely used for smoking cessation. It has shown efficacy over placebo and bupropion in manufacturer-sponsored trials. Those with mental illness were excluded from these trials.
Raidoo B Mahendri, Kutscher Eric C
doaj   +1 more source